Podcasts about mrna

Dr Joseph Sansone joins Ann Vandersteel and Dr Jane Ruby to discuss his battle to get the mRNA shots pulled off the market.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

Vacinas contra a covid-19 podem aumentar a sobrevida de pacientes com câncer? Separe trinta minutinhos do seu dia e descubra, com a Mila Massuda, como a tecnologia do mRNA pode potencializar tratamentos modernos contra tumores, fortalecer o sistema imunológico e impulsionar a imunoterapia no combate ao câncer.Apresentação: Mila Massuda (@milamassuda)Roteiro: Mila Massuda (@milamassuda) e Emilio Garcia (@emilioblablalogia)Revisão de Roteiro: Vee Almeida e Caio de Santis (@caiodesantis) Técnico de Gravação: Julianna Harsche (@juvisharsche)Editora: Angélica Peixoto (@angewlique)Mixagem e Masterização: Caio de Santis (@caiodesantis) Produção: Prof. Vítor Soares (@profvitorsoares), Matheus Herédia (@Matheus_Heredia), BláBláLogia (@blablalogia), Caio de Santis (@caiodesantis) e Biologia em Meia Hora (@biologiaemmeiahora)Gravado e editado nos estúdios TocaCast, do grupo Tocalivros (@tocalivros)REFERÊNCIASGRIPPIN, A. J. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature, p. 1–10, 22 out. 2025.

Witam Państwa, nazywam się Jarosław Drożdż, pracuję w Centralnym Szpitalu Klinicznym Uniwersytetu Medycznego w Łodzi, skąd nagrywam podcast Kardio Know-How. W tym odcinku rozpoczynam kontynuuję omawianie doniesień z tegorocznego kongresu AHA.Przeanalizowałem ponownie prezentacje z AHA 2025 i na drugim miejscu najważniejszych przełomów stawiam nowoczesne terapie lipidowe oparte na mRNA i edycji genów. Choć kardiologia wciąż opiera się głównie na klasycznej farmakoterapii, pojawiają się już u nas technologie znane z onkologii — przeciwciała monoklonalne i terapie oparte na RNA. W Polsce mamy alirokumab i inklisiran w programie B.101, a 27 listopada odbędzie się webinar z prof. Chlebusem nt. nowego otwarcia programu (link: https://sanofi.zoom.us/j/92476088795?pwd=DzcZmFDH7j2PzjQg3tZYuejpMNilmz.1). Pierwszą część stanowi Olezarsen z badań CORE-TIMI 72 — lek działający na mRNA apoC-III, obniżający TG nawet o 70% i redukujący ryzyko ostrego zapalenia trzustki o 85%. Nie efekty kliniczne, lecz sama nowa koncepcja terapii mRNA jest tu dla mnie kluczowa, choć aktualne badania pokazały nieoczekiwany wzrost LDL o ok. 50%. Mechanizm Olezarsenu opiera się na antysensownym oligonukleotydzie GalNAc3 kierowanym do hepatocytów i degradacji mRNA APOC3, co derepresjonuje lipazę lipoproteinową i przyspiesza klirens TG. Wyniki wraz z udziałem prof. Banacha opublikowano w NEJM: https://www.nejm.org/doi/abs/10.1056/NEJMoa2512761 oraz wcześniejsze dane: https://www.nejm.org/doi/full/10.1056/NEJMoa2507227. Drugą częścią nowości jest edycja genu ANGPTL3 — białka regulującego metabolizm lipidów, którego naturalne warianty utraty funkcji obniżają LDL i TG. Preparat CTX310 zawiera CRISPR-Cas9 zamknięty w nanocząsteczkach lipidowych i w badaniu fazy I (rok obserwacji) wykazał przede wszystkim bezpieczeństwo stosowania. To początek fascynującej drogi, która może w przyszłości doprowadzić do trwałego obniżania lipidów jednorazową terapią genową. Najnowsze doniesienia NEJM sugerują, że era leczenia aterogenezy poprzez edycję genów właśnie się rozpoczyna (https://www.nejm.org/doi/10.1056/NEJMoa2511778).Szczegółowy TRANSKRYPT do odcinka.Podcast jest przeznaczony wyłącznie dla osób z profesjonalnym wykształceniem medycznym.

A recent study found a link between mRNA vaccination and improved cancer immunotherapy response. The preclinical data demonstrated impressive results, leading to big questions. “We believe that [vaccination] actually does generate and even converts the cold tumors to hot tumors,” Steven H. Lin, MD, PhD, a physician-scientist and radiation oncologist at the University of Texas MD Anderson Cancer Center in Houston, tells Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer Center in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology.

“Welcome, welcome our wonderful audience!” Dr. Peter Breggin opened The Breggin Hour this week, talking about the effects of his stroke and about our efforts to seek rehabilitation, offering the best chance of optimizing recovery from brain damage. The indomitable Karen Kingston, who has been exposing the dangers of the mRNA vaccines for over five years, joined us. Peter spent a portion of the hour further detailing his experience of receiving treatment at the AVIV clinic, which offers a very specialized program of Hyperbaric Oxygen Treatment (HBOT). Peter made a comment at some point in the program, stating we must “muster great courage equal to our fear…” That phrase sums up for me my husband's attitude since his stroke. He is forging ahead, determined to embrace with both arms the work required to heal. During the third segment, we lost audio with Karen Kingston, so Peter and I finished up discussing artificial intelligence, and Karen's point that AI has been introduced just at a time when the human population is suffering from unprecedented amounts of neurological damage, from the mRNA vaccines as well as from other sources. She pointed out that the creators of the AI programs being used were doing the thinking—the cognitive work—for the individuals using it, which means humans are doing less independent thinking and creating increasing dependency upon outside sources. The neuropsychiatric damage done by mRNA vaccines is being clearly identified. Peter was a coauthor, along with other noted experts, of a recently published scientific paper: “Association Between COVID-19 Vaccination and Neuropsychiatric Conditions,” published in the International Journal of Innovative Research in Medical Science. The paper details over 58 profound neurological adverse effects resulting from mRNA vaccines. Dr. James Thorp spearheaded this research as lead author. The show was a mix of the deeply personal and an examination of some of the threats to humanity's future, with some sweet moments between Peter and Ginger.

Dr Joseph Sansone joins me live to unpack the latest development in his Florida mRNA court case after the 1DCA dismissed his appeal and pushed the fight back into the trial court. His amended complaint brings together months of studies, affidavits, medical documentation and official statements that challenge the ongoing distribution of mRNA injections in the state. This episode walks through why the case is intensifying and what this pivotal shift means for the battle ahead.Supermassive Black Coffee is crafted from organic, gourmet beans fire-roasted in an antique Victorian-era roaster, delivering the rich, smooth, non-acidic taste that reminds you this is how coffee was always meant to be. Use code JEFF50 for 50% off your first order. https://supermassiveblackcoffee.com/?ref=JEFFFollow Dr Joseph Sansone on Pickax: https://pickax.com/phdsansoneFollow Jeff Dornik on Pickax: https://pickax.com/jeffdornikTune into The Jeff Dornik Show LIVE every Tuesday and Thursday at 1pm ET. Subscribe on Rumble and never miss a show. https://rumble.com/c/jeffdornikBig Tech is silencing truth while farming your data to feed the machine. That's why I built Pickax… a free speech platform that puts power back in your hands and your voice beyond their reach. Sign up today:https://pickax.com/?referralCode=y7wxvwq&refSource=copy

In Tests hat sich der mRNA-Impfstoff als wirksamer gegen Grippe erwiesen als herkömmlicher Impfstoff, es gab aber mehr Impfreaktionen. Im Notfall kann er schnell hergestellt werden. Denn Fachleute beobachten mit Sorge die Verbreitung der Vogelgrippe. Budde, Joachim www.deutschlandfunk.de, Forschung aktuell

Seynsche, Monika www.deutschlandfunk.de, Forschung aktuell

From CFTR modulators to gene therapy, what's next in cystic fibrosis research? Peter Mogayzel examines future therapies, ongoing access challenges, and the crucial link between advocacy, innovation, and global health equity in cystic fibrosis care. Timestamps: 00:00 – Introduction 01:05 - CFTR modulators 03:35 – Anti-inflammatory drugs 04:18 – mRNA therapy 04:53 – Side effects 07:13 – Access to care 08:37 – Exercise 10:00 – Final thoughts

This week, we look at new research on potassium optimization in patients with defibrillators, reducing antihypertensive therapy in nursing homes, an mRNA influenza vaccine, and belzutifan for rare neuroendocrine tumors. We review long QT syndrome and present a case of abnormal behavior and seizures in a young man. We also explore perspectives on primary care reform, tobacco cessation in HIV and tuberculosis care, corporate control in health care, and the simple power of compassion with ice cream.

What happens when mRNA meets lipid nanoparticles? Sparks fly—and science wins. This dynamic duo is behind breakthroughs from game-changing vaccines to strategies for silencing stubborn viruses.Join Dodi and Conor as they sit down with Professor Sharon Lewin, a global leader in HIV research, to explore how this partnership could transform treatment and rewrite the future of medicine.Smart science, big ideas—don't miss this episode of Discovery Matters, brought to you by Cytiva.

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

FREEDOM - HEALTH - HAPPINESSThis podcast is highly addictive and seriously good for your health.SUPPORT DOC MALIK To make sure you don't miss any episodes, have access to bonus content, back catalogue, and monthly Live Streams, please subscribe to either:The paid Spotify subscription here: ⁠⁠https://creators.spotify.com/pod/show/docmalik/subscribe⁠⁠ The paid Substack subscription here: ⁠⁠https://docmalik.substack.com/subscribe⁠⁠Thank you to all the new subscribers for your lovely messages and reviews! And a big thanks to my existing subscribers for sticking with me and supporting the show! ABOUT THIS CONVERSATION: In this episode I break down what I believe is one of the greatest scandals of our time. We were never given informed consent during COVID, and the truth is we still are not being given it today. From lockdowns to masking to the mRNA jab, from digital ID to central bank digital currencies, fifteen minute cities, net zero and the entire climate agenda, none of this has ever been honestly explained to the public. We have been managed, manipulated and coerced, not informed.This conversation was inspired by the work of Elizabeth Hart and a letter she shared with me that she sent to Professor Angus Dalgleish. Her research opened my eyes even further to how the medical profession, governments, PR machines, academic institutions and billionaire funded organisations shaped the narrative to manufacture compliance, not understanding.I talk openly about the failures of my own former profession, the coercion admitted by supposed experts, and the reality that anyone who pushed these products and still promotes them today has no place claiming leadership in any freedom movement.This is a call to clarity, a call to sovereignty, and a reminder that the entire system rests on our consent. Once we stop giving it, the spell breaks.This episode will challenge you, provoke you, and hopefully empower you to think differently.Enjoy the episode.See my substack for more info. Much love, as always.Doc MalikIMPORTANT INFORMATIONCONSULTATION SERVICEIn a world of rushed 7-minute consultations and endless referrals, I offer you something rare: time, context, and clear guidance.As your health advocate, I can help you:Understand your diagnosis and decode medical jargonDecide who to see: GP, specialist, osteopath, physio, accupuntcurist, homeopath etc?Break down treatment plans in plain, easy to understand non jargon EnglishPrepare for surgery, understand your risks, obtain true informed consent, and optimise yourself pre-op Recover from surgery, advise you how to heal faster and quicker and minimise post-op complicationsManage chronic illness with lifestyle, mindset, and dietary changesExplore holistic options that complement conventional careAsk better questions, and get real answersGet an unbiased second opinionReady to Take Control?If you're navigating a health concern, preparing for a big decision, or simply want to feel more confident in your path forward, I'd love to support you.Book here ⁠⁠ https://docmalik.com/consultations/ ⁠⁠Because it's your body, your life, and your future. Let's make sure you're informed and heard.SeagreenIf you want to support your health naturally, I highly recommend trying Sea Greens, a rich source of bioavailable iodine and trace minerals that nourish thyroid function, balance hormones, and provide a clean daily boost from wild ocean plants. Use the code DOCMALIK⁠⁠https://seagreens.shop/⁠⁠WaterpureI distill all my water for drinking, washing fruit and vegetables, and cooking. If you knew what was in tap water, so would you!⁠⁠https://waterpure.co.uk/docmalik BUY HERE TODAY⁠⁠Hunter & Gather FoodsSeed oils are inflammatory, toxic and nasty; eliminate them from your diet immediately. Check out the products from this great company⁠⁠https://hunterandgatherfoods.com/?ref=DOCHG BUY HERE TODAY⁠⁠Use DOCHG to get 10% OFF your purchase with Hunter & Gather Foods.

What if the tumor you're treating is already yesterday's news? In this riveting episode of Metabolic Matters, Dr. Nasha Winters sits down with Dr. John A. Catanzaro, NMD, PhD—Co-Founder and CEO of Neo7Bioscience and one of the leading innovators in personalized peptide therapeutics and molecular surveillance. With over 25 years at the intersection of clinical medicine, molecular biology, and translational research, Dr. Catanzaro specializes in understanding the real-time biology driving cancer, autoimmunity, chronic inflammation, degenerative disease, and mRNA-related injuries. His proprietary PBIMA® and REViSS® platforms analyze genomics, transcriptomics, proteomics, and AHI-driven analytics to design patient-specific peptide sequences tailored to each individual's molecular signature.Connect with Dr. John: WebsiteDr. John's XNeoScience XFacebookSubstack Dr. John LinkedInNeoScience LinkedInNeoScience YoutubeAbout Your HostI'm Dr. Nasha Winters, a global healthcare authority, best-selling author, and educator in the emerging field of integrative oncology and terrain-based cancer care. I host Metabolic Matters to explore the intersections between metabolism, medicine, and meaning.Subscribe, Share & ReviewIf you loved this conversation, please subscribe, rate, and share with a friend or clinician who needs to hear it.Support & Resources:Support Patient Grants: www.mtih.orgBook: The Metabolic Approach to CancerEducation Programs: www.metabolicregen.comSupplements: mitovida.comFollow on SocialsDr. Nasha on InstagramMetabolic Matters InstagramFacebookLinkedInTikTokYouTube Hosted on Acast. See acast.com/privacy for more information.

A sweeping conversation about how modern systems keep us nutritionally weak, spiritually dulled, and biologically confused — and how simply eating "food for humans" can reverse disease, restore vitality, and reconnect us to the sacred design behind our bodies. Paul Saladino dismantles processed-food orthodoxy, exposes the institutional incentives that keep us sick, and lays out a path back to strength, sovereignty, and clear thinking — from meat and mitochondria to seed oils, vaccines, addiction, metabolic disease, and the spiritual dimension of reclaiming health. Paul's book ("The Carnivore Code") — His foundational work on nutrient-dense eating, environmental toxins, and how animal-based nutrition can heal modern chronic illness: https://bit.ly/saladinobook Paul's website — Articles, research breakdowns, and his podcast "Fundamental Health," where he explores food, biology, psychology, and human thriving: https://www.paulsaladinomd.co Study mentioned in the ad — A new peer-reviewed paper cited by The Wellness Company reporting a potential association between mRNA vaccination and increased cancer risk, based on population-level biomarker analysis: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00831-W

The Breggin Hour with Dr. Peter & Ginger Breggin – Karen's point that AI has been introduced just at a time when the human population is suffering from unprecedented amounts of neurological damage, from the mRNA vaccines as well as from other sources. She pointed out that the creators of the AI programs being used were doing the thinking—the cognitive work—for the individuals using it, which...

In this episode of ScaleUp Radio, we're diving into the groundbreaking world of personalised cancer treatments with Prasun Chakraborty, founder of Genevation – a biotech startup on a mission to revolutionise how we treat and potentially prevent cancer. Unlike the traditional one-size-fits-all approach to oncology, Genevation is using advanced AI and genetic sequencing to create custom mRNA cancer vaccines for individual patients – in just 14 days. Prasun shares the inspiring story behind the business, the massive challenges of scaling deep-tech biotech, and his clear vision of a future where cancer is not just treatable, but preventable. The conversation unfolds in three parts: Genevation's Business Model & Scaleup Journey From solo founder in 2022 to a lean but mighty team with key strategic partnerships, Prasun explains how Genevation is disrupting the cancer treatment space with a personalised, tech-first model that sidesteps the traditional limitations of clinical research. Scaling Challenges in Biotech & Beyond Prasun reflects on the key hurdles facing deep-tech startups – especially the funding gap created by investors' lack of scientific understanding and the fixation on short-term ROI. He shares candid insights into how Genevation is navigating these barriers and what it will take to unlock their next phase of growth. Quickfire Insights We round off with some powerful reflections from Prasun on leadership, mindset, and why it's essential to stay focused on the mission, even when the money and metrics don't align. Key Highlights: Genevation's AI algorithm cuts vaccine candidate selection time from 4 hours to 5 minutes. Preclinical data shows a single dose prevented tumour growth for 13 days in lung cancer models. The company is raising $5M to fund its IND application and unlock further investment. Strategic partners like Google, NVIDIA, AWS, and Illumina are backing Genevation with substantial resources. There's a lot in here – from AI innovation to biotech regulation, from strategic partnerships to the raw reality of raising millions in funding just to prove your concept. "Every cancer is unique – and it's time our treatments reflect that." Make sure you don't miss any future episodes by subscribing to ScaleUp Radio wherever you like to listen to your podcasts – and why not give us a follow. For now, continue listening for the full discussion with Prasun. Scaling up your business isn't easy, and can be a little daunting. Let ScaleUp Radio make it a little easier for you. With guests who have been where you are now, and can offer their thoughts and advice on several aspects of business. ScaleUp Radio is the business podcast you've been waiting for. If you would like to be a guest on ScaleUp Radio, please click here: https://bizsmarts.co.uk/scaleupradio/kevin You can get in touch with Kevin & Granger here: kevin@biz-smart.co.uk grangerf@biz-smart.co.uk   Kevin's Latest Book Is Available! Drawing on BizSmart's own research and experiences of working with hundreds of owner-managers, Kevin Brent explores the key reasons why most organisations do not scale and how the challenges change as they reach different milestones on the ScaleUp Journey. He then details a practical step by step guide to successfully navigate between the milestones in the form of ESUS - a proven system for entrepreneurs to scale up. More on the Book HERE - https://www.esusgroup.co.uk/   Prasun can be found here: https://www.linkedin.com/in/prasun-chakraborty-5090851b6/  

This Week in Review recaps ex-CDC Director Robert Redfield decrying mRNA vaccines as immunotoxic for healthy people while praising cancer applications, Stephen Miller's confident economic timeline from cheaper Thanksgiving to tax relief and nuclear revival, Florida SG Joseph Ladapo warning of enslavement forces at CHD conference, Elon Musk affirming Christ's teachings on forgiveness, and poll results demanding 68% for Trump to focus solely on domestic issues amid listener reactions.   AM Update Week in Review, Robert Redfield mRNA, Stephen Miller economy, Joseph Ladapo freedom, Elon Musk Christ, domestic focus poll, vaccine injury, affordability timeline, transhumanism warning, Trump priorities

Diagnostic radiologist Rakesh A. Shah discusses his article "A critique of medicine's response to RFK Jr." Rakesh argues that major physician organizations have failed in their duty to protect public health by remaining silent and timid in the face of Robert F. Kennedy Jr.'s anti-vaccine misinformation. He contends that this "cowardice" prioritizes institutional self-interest over patient welfare and endangers not just immunization programs but the future of medical research, including promising mRNA-based cancer treatments. This episode explores the crisis of leadership in organized medicine, the difference between being apolitical and surrendering to a public health threat, and why Rakesh believes this silence is a profound abdication of professional duty. Learn why he argues that when politicians show more courage than doctors, the very credibility of medicine is at stake. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

In this explosive interview, Dr. Peter McCullough and epidemiologist Nicolas Hulscher expose the untold history, ideology, and corruption behind the global vaccine narrative — from Cotton Mather and Louis Pasteur to Fauci and the modern mRNA era. They reveal shocking evidence of contaminated polio shots, untested childhood vaccine schedules, and the CDC's deceptive reporting tactics that have silenced doctors who dare to question “the science.” Together, they uncover how fear, power, and profit created a modern-day religion of vaccinology that has replaced faith in God with faith in pharmaceuticals. Dr. McCullough also dives deep into the disturbing genetic chaos caused by mRNA shots — linking them to turbo cancers, blood clots, dementia, infertility, and transgenerational harm. They also discuss the alarming normalization of disease, the rise of autism and gender confusion, and the moral collapse of medicine that's putting children at risk. This is one of the most eye-opening conversations ever released on the Rebecca Weiss Podcast — a must-watch for anyone who values truth, freedom, and medical autonomy.

In this explosive interview, Dr. Peter McCullough and epidemiologist Nicolas Hulscher expose the untold history, ideology, and corruption behind the global vaccine narrative — from Cotton Mather and Louis Pasteur to Fauci and the modern mRNA era. They reveal shocking evidence of contaminated polio shots, untested childhood vaccine schedules, and the CDC's deceptive reporting tactics that have silenced doctors who dare to question “the science.” Together, they uncover how fear, power, and profit created a modern-day religion of vaccinology that has replaced faith in God with faith in pharmaceuticals. Dr. McCullough also dives deep into the disturbing genetic chaos caused by mRNA shots — linking them to turbo cancers, blood clots, dementia, infertility, and transgenerational harm. They also discuss the alarming normalization of disease, the rise of autism and gender confusion, and the moral collapse of medicine that's putting children at risk. This is one of the most eye-opening conversations ever released on the Rebecca Weiss Podcast — a must-watch for anyone who values truth, freedom, and medical autonomy.

[00:01:03] – Trump's Veterans Day with an Al-Qaeda LeaderKnight opens with outrage over Trump meeting a Syrian warlord linked to Al-Qaeda, framing it as proof of U.S. hypocrisy and the intelligence community's long alliance with terrorist networks. [00:06:56] – The 50-Year Mortgage and Debt SlaveryHe mocks Trump's plan for 50-year mortgages as the next stage of financial serfdom, arguing that Americans will “own nothing” while banks and the state profit from endless debt cycles. [00:42:06] – The CIA and the Birth of the Feral GovernmentKnight traces the origins of the national security state, accusing Truman's creation of the CIA and NSA of birthing an unaccountable “feral government” that now rules America through secrecy and surveillance. [01:09:19] – Feeding Candy to Cattle and mRNA MeatHe exposes candy companies selling waste candy as cattle feed and the USDA's quiet approval of mRNA livestock vaccines, calling it a convergence of food corruption and biotech experimentation. [01:11:22] – The FACE Act and Criminalized SpeechKnight examines how the FACE Act is being used to prosecute both pro-life and anti-war activists, warning it's a bipartisan tool for suppressing free expression under moral pretense. [01:34:13] – The Universities as Marxist SeminariesKnight argues modern academia has become an ideological indoctrination system rooted in the Frankfurt School — designed to dismantle faith, family, and free enterprise from within. [01:45:33] – The Clinton Foundation's Untouchable CrimesHe revisits Trump's refusal to pursue investigations into the Clinton Foundation, describing it as evidence of systemic bipartisan corruption shielding globalist elites. [02:03:06] – The Medical Coder Whistleblower: Zoe Smith's TestimonySmith exposes how hospitals received federal bonuses for COVID diagnoses and ventilator use, revealing how financial incentives turned healthcare into a profit-driven death machine. [02:23:37] – PCR Tests and Genetic Data HarvestingSmith explains that PCR testing was repurposed from diagnostic use into mass data collection, linking it to global DNA databases used for AI-driven biotech development. [02:59:40] – Cash Bans and the Digital Totalitarian FutureKnight closes warning that Europe's cash bans and central bank digital currencies represent the final step toward total economic surveillance and the end of financial freedom. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[00:01:03] – Trump's Veterans Day with an Al-Qaeda LeaderKnight opens with outrage over Trump meeting a Syrian warlord linked to Al-Qaeda, framing it as proof of U.S. hypocrisy and the intelligence community's long alliance with terrorist networks. [00:06:56] – The 50-Year Mortgage and Debt SlaveryHe mocks Trump's plan for 50-year mortgages as the next stage of financial serfdom, arguing that Americans will “own nothing” while banks and the state profit from endless debt cycles. [00:42:06] – The CIA and the Birth of the Feral GovernmentKnight traces the origins of the national security state, accusing Truman's creation of the CIA and NSA of birthing an unaccountable “feral government” that now rules America through secrecy and surveillance. [01:09:19] – Feeding Candy to Cattle and mRNA MeatHe exposes candy companies selling waste candy as cattle feed and the USDA's quiet approval of mRNA livestock vaccines, calling it a convergence of food corruption and biotech experimentation. [01:11:22] – The FACE Act and Criminalized SpeechKnight examines how the FACE Act is being used to prosecute both pro-life and anti-war activists, warning it's a bipartisan tool for suppressing free expression under moral pretense. [01:34:13] – The Universities as Marxist SeminariesKnight argues modern academia has become an ideological indoctrination system rooted in the Frankfurt School — designed to dismantle faith, family, and free enterprise from within. [01:45:33] – The Clinton Foundation's Untouchable CrimesHe revisits Trump's refusal to pursue investigations into the Clinton Foundation, describing it as evidence of systemic bipartisan corruption shielding globalist elites. [02:03:06] – The Medical Coder Whistleblower: Zoe Smith's TestimonySmith exposes how hospitals received federal bonuses for COVID diagnoses and ventilator use, revealing how financial incentives turned healthcare into a profit-driven death machine. [02:23:37] – PCR Tests and Genetic Data HarvestingSmith explains that PCR testing was repurposed from diagnostic use into mass data collection, linking it to global DNA databases used for AI-driven biotech development. [02:59:40] – Cash Bans and the Digital Totalitarian FutureKnight closes warning that Europe's cash bans and central bank digital currencies represent the final step toward total economic surveillance and the end of financial freedom. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Očkovanie je zázrak a možno s antibiotikami najväčší medicínsky objav ľudstva. Teraz sa zdá, že nové mRNA vakcíny by mohli pomáhať proti ďalším problémom: mohli by zastaviť alergie. Tento týždeň sa v podcaste Zoom pozrieme na očkovanie proti alergiám a dozvieme sa, ako je to so žralokmi a útokmi na ľudí. – Všetky podcasty denníka SME si môžete vypočuť na jednom mieste na podcasty.sme.sk. – Ak máte pre nás spätnú väzbu, odkaz alebo nápad, napíšte nám na podcasty@sme.sk – Odoberajte aj (Ne)vedecký newsletter Tomáša Prokopčáka na sme.sk/nevedecky – Ďakujeme, že počúvate podcast Zoom.See omnystudio.com/listener for privacy information.

Angel Studios https://Angel.com/HermanJoin the Angel Guild today and know you are not just watching, you're helping make bold, faith driven stories like Disciples in the Moonlight possible. That's Angel.com/HermanRenue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar November 20th 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at (SLOW) Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.Ben Shapiro has become a hall monitor, per se. There are certain things you can't talk about. You cannot question the government of Israel around Ben Shapiro, and up until very recently, you couldn't ask questions about the mRNA injections.Episode Links:Mark Levin reads private text messages with Tucker Carlson revealing that TPUSA wanted the two men to debate. Carlson said he was open to debate but Levin refused because he didn't want to “platform” Carlson. Levin then bragged about his “rational” response where he called Carlson “the modern-day David Duke.” What a bizarre response.“I don't want to have a war with Ben Shapiro...” @TuckerCarlson on whether he and Ben Shapiro can find a way to detente.Qatar sent millions to Gaza for years – with Israel's backing. Here's what we know about the controversial dealFormer Capitol Police officer a forensic match for Jan. 6 pipe bomber, sources sayBen Shapiro admitting we were lied to by everyone including Pfizer, the government & the scientists compiled with new clips of him shaming people for asking question

Aaron McIntire breaks down President Trump's push to reopen the federal government amid a Democrat's candid revelation on party entrenchment in Obamacare subsidies. Plus, Trump's bold vision for direct-to-citizen healthcare payments and $2,000 tariff dividends to tackle national debt; Supreme Court sidesteps "same-sex marriage" challenge but takes on post-Election Day ballots; Olympics eye blanket transgender athlete ban; updates on Ilhan Omar's deportation defiance, Elon Musk's AI prison rethink, GOP cooling on marijuana, the deepening Cybertruck bombing mystery, ex-CDC chief's mRNA vaccine regrets, and a big-picture warning on transhumanism's power grab.   government shutdown, Trump healthcare, tariff dividends, Supreme Court cases, same-sex marriage, election ballots, Olympics transgender ban, Ilhan Omar, Elon Musk AI, marijuana legalization, Cybertruck bombing, mRNA vaccines, Robert Redfield, transhumanism

From his early days as a Peace Corps volunteer in Benin to leading the world's first clinical trial of an mRNA-based malaria vaccine, Matthew Laurens, MD, MPH's, career journey in global health highlights how a passion for service can lead to transformative global impact.

Denne episoden er vaksinert, er du? I dag møter du kunnskapsløse Sondre med raske spørsmål. Sammen i studio står Lars, som illustrerer kroppens repons til vaksiner, med et sprinkel av USA-forakt! SIlje derimot er ellegant i sin opptreden, med stabile, gode, smarte og pedagogisk reonementer rundt flokkimmunitet, mRNA, og potensielt hvordan å utslette kreft! Om du vil høre fra gutta krutt eller silje den fantastiske, lytt til denne episoden!

Over the last five years, billions of people have received at least one dose of a COVID-19 mRNA vaccine. New research has found an unanticipated result of these vaccines: Cancer treatments are more effective for some vaccinated patients, and many live longer than their unvaccinated counterparts. This news comes at a time where the federal government is slashing funding for mRNA research. Host Ira Flatow speaks to lead study author Adam Grippin and vaccine expert Eric Topol.Guests: Dr. Adam Grippin is a radiation oncologist at the MC Anderson Cancer Center in Houston, Texas. Dr. Eric Topol is a cardiologist and genomics professor at the Scripps Research Institute in La Jolla, California.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Numerous COVID-19 Vaccine Studies Point to Overwhelming Risks. Dr. McCullough, Dr. Nicolas Hulscher and 8 X Shorts. Nicolas Hulscher  BREAKING: Two Studies Confirm COVID-19 "Vaccines" Act as Chemical Lobotomies — 146 Serious Brain, Spinal Cord, and Psychiatric Adverse Events Identified CDC/FDA safety signals BREACHED for prion disease, encephalitis, brain abscesses, dementia, schizophrenia, suicidal and homicidal thoughts, stroke, psychosis, depression, cognitive impairment, delusions, meningitis, myelitis, demyelination syndromes, and MANY more. The shots disrupt the blood–brain barrier, allowing mRNA, amyloidogenic spike proteins and pathogens to penetrate the brain and spinal cord — an outcome consistent with the skyrocketing rates of cognitive decline now seen across the world. 8 X Shorts on Vaccination Risks. --------------------------------------------------------------------  Check out our ACU Patreon page: https://www.patreon.com/ACUPodcast   HELP ACU SPREAD THE WORD!  Please go to Apple Podcasts and give ACU a 5 star rating. Apple canceled us and now we are clawing our way back to the top. Don't let the Leftist win. Do it now! Thanks. Also Rate us on any platform you follow us on. It helps a lot. Forward this show to friends. Ways to subscribe to the American Conservative University Podcast Click here to subscribe via Apple Podcasts Click here to subscribe via RSS You can also subscribe via Stitcher FM Player Podcast Addict Tune-in Podcasts Pandora Look us up on Amazon Prime …And Many Other Podcast Aggregators and sites ACU on Twitter- https://twitter.com/AmerConU . Warning- Explicit and Violent video content.   Please help ACU by submitting your Show ideas. Email us at americanconservativeuniversity@americanconservativeuniversity.com   Endorsed Charities -------------------------------------------------------- Pre-Born! Saving babies and Souls. https://preborn.org/ OUR MISSION To glorify Jesus Christ by leading and equipping pregnancy clinics to save more babies and souls. WHAT WE DO Pre-Born! partners with life-affirming pregnancy clinics all across the nation. We are designed to strategically impact the abortion industry through the following initiatives:… -------------------------------------------------------- Help CSI Stamp Out Slavery In Sudan Join us in our effort to free over 350 slaves. Listeners to the Eric Metaxas Show will remember our annual effort to free Christians who have been enslaved for simply acknowledging Jesus Christ as their Savior. As we celebrate the birth of Christ this Christmas, join us in giving new life to brothers and sisters in Sudan who have enslaved as a result of their faith. https://csi-usa.org/metaxas   https://csi-usa.org/slavery/   Typical Aid for the Enslaved A ration of sorghum, a local nutrient-rich staple food A dairy goat A “Sack of Hope,” a survival kit containing essential items such as tarp for shelter, a cooking pan, a water canister, a mosquito net, a blanket, a handheld sickle, and fishing hooks. Release celebrations include prayer and gathering for a meal, and medical care for those in need. The CSI team provides comfort, encouragement, and a shoulder to lean on while they tell their stories and begin their new lives. Thank you for your compassion  Giving the Gift of Freedom and Hope to the Enslaved South Sudanese -------------------------------------------------------- Food For the Poor https://foodforthepoor.org/ Help us serve the poorest of the poor Food For The Poor began in 1982 in Jamaica. Today, our interdenominational Christian ministry serves the poor in primarily 17 countries throughout the Caribbean and Latin America. Thanks to our faithful donors, we are able to provide food, housing, healthcare, education, fresh water, emergency relief, micro-enterprise solutions and much more. We are proud to have fed millions of people and provided more than 15.7 billion dollars in aid. Our faith inspires us to be an organization built on compassion, and motivated by love. Our mission is to bring relief to the poorest of the poor in the countries where we serve. We strive to reflect God's unconditional love. It's a sacrificial love that embraces all people regardless of race or religion. We believe that we can show His love by serving the “least of these” on this earth as Christ challenged us to do in Matthew 25. We pray that by God's grace, and with your support, we can continue to bring relief to the suffering and hope to the hopeless.   Report on Food For the Poor by Charity Navigator https://www.charitynavigator.org/ein/592174510   -------------------------------------------------------- Disclaimer from ACU. We try to bring to our students and alumni the World's best Conservative thinkers. All views expressed belong solely to the author and not necessarily to ACU. In all issues and relations, we hope to follow the admonitions of Jesus Christ. While striving to expose, warn and contend with evil, we extend the love of God to all of his children. ----------------------------------------------------------------------------------------- 

RFK Jr. says that new dietary guidelines will be released in December and he claims they will change food culture in the U.S. We can hope this change is positive, but considering how RFK Jr has backed mRNA, rubber stamped a MAHA report with AI writing and errors, and push processed prepared meals, the change might be negative. Already the USDA recommends vegetables and fruits, but RFK Jr. has hinted how the new guidelines will include more promotion of meat and dairy products, though he say “Whole Foods” will be a big part of the new guidance. Is it possible the guidelines get worse? Does it matter when few consult them to begin with? What does it matter when some States try to independently start initiatives that lack funding and respect anyway? Even if the entire government of every state moved in a positive direction is it possible the public would rebel? At the core of this problem is a cultural issue that neglects food education, or what the Japanese call Shokuiku, and it extends to healthcare in general. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKWEBSITEBuyMe-CoffeePaypal: rdgable1991@gmail.comCashApp: $rdgable EMAIL: rdgable@yahoo.com /TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

People undergoing immunotherapy treatment for cancer and who got a Covid vaccine survived longer than those who did not get the vaccine, a new study finds. Jeff Coller, an mRNA expert at Johns Hopkins, examines why this hasn't been seen … Why haven't we seen cancer fighting effects with vaccines other than the Covid vaccines? Elizabeth Tracey reports Read More »

mRNA vaccines can help the body fight cancer, a new study found, yet when we look at what has been called ‘vaccine hesitancy' we see many people are suspicious of vaccines in general, let alone mRNA vaccines. Johns Hopkins mRNA … Why were so many people hesitant to take mRNA vaccines? Elizabeth Tracey reports Read More »

Covid vaccines boosted the immune response in people being treated for cancer and improved their survival, a recent study concludes. mRNA expert Jeff Coller at Johns Hopkins says as more evidence mounts establishing the benefits of mRNA vaccines, we need … Many vaccines are intended to reduce disease severity, Elizabeth Tracey reports Read More »

People with lung cancer and melanoma who were receiving immunotherapies and got a Covid vaccine saw dramatically improved survival compared with folks who did not get the vaccine, a recent study shows. mRNA expert Jeff Coller at Johns Hopkins muses … What is it about mRNA vaccines that helps us fight cancer? Elizabeth Tracey reports Read More »

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses the link between in utero SARS-CoV-2 infection and poor neurodevelopment outcomes, the use of an mRNA vaccine as an anti-cancer therapy, why one should receive the HPV vaccine, asymptomatic H5N1 isolations in humans, and H5N1 on turkey farms, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how two vaccinated physicians became infected with measles, effective of COVID-19 vaccine for children, where to find PEMGARDA, how to access and pay for Paxlovid, can you be retreated with Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, how a specific antibody type may associate with recovery from long COVID, if use of a probiotic is helpful to treat mild COVID-19, if vaccination helps prevent long in adolescents and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Neurodevelopmental Outcomes of 3-Year-Old Children Exposed to Maternal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Utero (Obstetrics & Gynecology) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (Nature) TWiV 1267: A cancer vaccine and an mpox treatment (microbeTV: TWiV1267) Cancers Caused by HPV (CDC: Human papillomavirus (HPV)) Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection (Journal of National Cancer Institute) Impact of Vaccinating Adult Women Who Are HPV-Positive or with Confirmed Cervical SIL with the 9-Valent Vaccine (Viruses) ACIP Shared Clinical Decision-Making Recommendations (CDC: Advisory Committee on Immunization Practices (ACIP)) HPV Vaccination Recommendation (CDC: Vaccines & Immunizations) Asymptomatic Human Infections With Avian Influenza A(H5N1) Virus Confirmed by Molecular and Serologic Testing (JAMA: OPEN Network) Review: Human H5N1 avian flu cases can be asymptomatic, and the virus likely spreads among people (CIDRAP) Avian flu strikes turkey farms in Dakotas, large egg facility in California (CIDRAP) Another Doctor at Ichilov Contracts Measles After Treating Unvaccinated Child (gov.il) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England (LANCET: Child & Adolescent Health) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Real-World Effectiveness of Nirmatrelvir-Ritonavir in Preventing Coronavirus Disease 2019–Associated Hospitalization (CID) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID (Journal of Infection) Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19 (Infectious Diseases and Therapy) Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection (Vaccine) Reaching out to US house representative Letters read on TWiV 1268 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Filmed live before a studio audience, Del Bigtree and Jefferey Jaxen break down Bill Gates' shocking reversal on climate change — signaling that the global narrative may finally be unraveling. Then, a new American Heart Association study reveals alarming data on the COVID vaccine's impact on the heart — a discovery that could mark the final blow for mRNA technology. Plus, an unprecedented in-studio panel brings together Dr. Andrew Wakefield, Dr. Pierre Kory, and Dr. Suzanne Humphries — three medical truth-tellers confronting the biggest questions of our time: Are we witnessing the collapse of a system built on misinformation? Or the rebirth of true science and transparency?Watch this powerful new episode of The HighWire, where the truth always comes straight from the heart.Guests: Dr. Suzanne Humphries, Dr. Pierre Kory, Dr. Andrew WakefieldBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Thursday at 1pm ET, I'm joined live by Karen Kingston for a conversation that will challenge everything you think you know about science, story, and the language shaping modern belief. We'll explore how Hollywood films like Jurassic Park and JAWS may hold deeper analogies to the rise of mRNA technology—and how the manipulation of language itself has become a weapon against discernment. This is not just about movies or medicine; it's about truth, revelation, and reclaiming the moral imagination that defines what it means to be human.Think the mainstream media is manipulating you? Following the Leader pulls back the curtain on the shocking truth behind how global elites use propaganda and mass control to push their agenda—and it's far worse than you imagine. Pre-order your copy today! https://jeffdornik.com/ftlTune into The Jeff Dornik Show LIVE every Tuesday and Thursday at 1pm ET. Subscribe on Rumble and never miss a show. https://rumble.com/c/jeffdornikSubscribe to my Pickax account today and get my hard-hitting, uncensored email newsletter delivered straight to your inbox.https://pickax.com/jeffdornikBig Tech is silencing truth while farming your data to feed the machine. That's why I built Pickax… a free speech platform that puts power back in your hands and your voice beyond their reach. Sign up today:https://pickax.com/?referralCode=y7wxvwq&refSource=copy

On Election Day 2025, buckle up for a no-holds-barred episode. We're showing the White House's "My Safe Space" Facebook page— tribute to the Democrats—while unpacking bomb threats crippling New Jersey polling sites and voting machine glitches suspiciously targeting red districts. And in Virginia, Barack Obama's hypocritical endorsement of DEI-pushing Abigail Spanberger over trailblazing Black Republican Winsome Earle-Sears? We'll break down the left's "systemic racism" flip-flop with fiery audio that makes you question: politics or principles?Shifting gears to the Big Apple, Elon's torching NYC's mayoral ballot as a straight-up scam—no ID, duplicate names, Cuomo buried at the bottom. Then, meet Zohran Mamdani, the socialist firebrand whose "Democrat" word salad has street-level libs drooling over government-run grocery stores and "lifting everybody up" with zero clue on costs. We'll roll clips of clueless voters, a ranting communist vowing to seize food industries, and a white liberal's wildest worries: ICE raids on illegals and kids' sex changes. It's peak progressive absurdity, straight from the rallies—proving Europe's Muslim power grabs and Dearborn's call-to-prayer wake-ups are just a Mamdani win away.But it's not all outrage—join us for a raw, eye-opening chat with Vaccine Choice Canada's Ted Kuntz, whose son's DPT nightmare sparked a 40-year crusade for medical freedom. From underreported seizures to mRNA red flags, he'll torch the industry's "safety" lies and champion informed consent over herd immunity hype. We also have a blistering fax blast demanding Congress deport 'em all or face removal, slamming sanctuary treason from Pritzker to Omar. Tune in—because if we don't fight the invasion now, America's ballot box becomes its battlefield. Don't miss the untamed truth!

Internal medicine physician Harry Oken discusses his article "mRNA post vaccination syndrome: Is it real?" In this episode, Harry explores the science, uncertainty, and human stories surrounding post-vaccination syndrome (PVS) linked to mRNA COVID-19 vaccines. Drawing on clinical data and personal experience, he explains how lingering immune reactions may affect patients and why research is urgently needed to clarify causes and treatments. Harry emphasizes compassion, scientific rigor, and the importance of investigating rare outcomes without undermining public trust in vaccines. Viewers will gain a deeper understanding of PVS, ongoing studies like Yale's LISTEN project, and how medicine continues to balance innovation with safety. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

[00:02:55] – Trump's Tariff Dictatorship & Fake EmergenciesKnight calls Trump's “emergency tariffs” case the blueprint for economic dictatorship, saying Congress has handed the president Caesar-style powers to rule by declaration. [00:11:12] – The Punisher Police StateKnight exposes how law enforcement's obsession with the Punisher logo mirrors America's descent into militarized authoritarianism — a culture where violence replaces justice. [00:31:56] – Trump's Assault on the Rule of LawKnight argues Trump turned the Constitution into political theater, using “emergency powers” and a cult of personality to replace lawful governance with ego-driven tyranny. [00:53:39] – Elon Musk, H-1B, and the Technocratic TrapKnight tears into Musk's Rogan appearance, saying Musk's visa policies and AI automation push “top-down population replacement.” He brands Musk and Silicon Valley as “authoritarian overlords disguised as innovators.” [01:09:10] – The Masters of the Universe SpeechKnight plays footage from the Republican Jewish Coalition where a speaker boasts, “The masters of the universe are Jews.” [01:33:42] – Epstein Files, Mike Johnson & The Cover-UpKnight blasts Speaker Mike Johnson for blocking Epstein file releases, praising Marjorie Taylor Greene's promise to read names aloud in Congress. “The pedophile class,” he says, “owns both parties.” [01:45:09] – The Anti-Speech Laws & Real ID StateKnight condemns GOP-backed laws banning Israel criticism and mandating digital ID compliance, calling it the merger of Zionism and technocracy — censorship under the flag of patriotism. [02:19:20] – “mRNA Is Pure Poison”Dr. Brian Hooker says mRNA vaccines are a depopulation tool masked as medicine. He cites over a million U.S. deaths and calls for an outright ban on “Fauci's bioweapon empire.” [02:35:41] – Contamination & SV40 Cancer RiskHooker reveals vaccine contamination with E. coli and SV40 viral DNA — a known carcinogen. He calls it “DARPA's biotech soup,” proof that mRNA production was a reckless military experiment, not medicine. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[00:02:55] – Trump's Tariff Dictatorship & Fake EmergenciesKnight calls Trump's “emergency tariffs” case the blueprint for economic dictatorship, saying Congress has handed the president Caesar-style powers to rule by declaration. [00:11:12] – The Punisher Police StateKnight exposes how law enforcement's obsession with the Punisher logo mirrors America's descent into militarized authoritarianism — a culture where violence replaces justice. [00:31:56] – Trump's Assault on the Rule of LawKnight argues Trump turned the Constitution into political theater, using “emergency powers” and a cult of personality to replace lawful governance with ego-driven tyranny. [00:53:39] – Elon Musk, H-1B, and the Technocratic TrapKnight tears into Musk's Rogan appearance, saying Musk's visa policies and AI automation push “top-down population replacement.” He brands Musk and Silicon Valley as “authoritarian overlords disguised as innovators.” [01:09:10] – The Masters of the Universe SpeechKnight plays footage from the Republican Jewish Coalition where a speaker boasts, “The masters of the universe are Jews.” [01:33:42] – Epstein Files, Mike Johnson & The Cover-UpKnight blasts Speaker Mike Johnson for blocking Epstein file releases, praising Marjorie Taylor Greene's promise to read names aloud in Congress. “The pedophile class,” he says, “owns both parties.” [01:45:09] – The Anti-Speech Laws & Real ID StateKnight condemns GOP-backed laws banning Israel criticism and mandating digital ID compliance, calling it the merger of Zionism and technocracy — censorship under the flag of patriotism. [02:19:20] – “mRNA Is Pure Poison”Dr. Brian Hooker says mRNA vaccines are a depopulation tool masked as medicine. He cites over a million U.S. deaths and calls for an outright ban on “Fauci's bioweapon empire.” [02:35:41] – Contamination & SV40 Cancer RiskHooker reveals vaccine contamination with E. coli and SV40 viral DNA — a known carcinogen. He calls it “DARPA's biotech soup,” proof that mRNA production was a reckless military experiment, not medicine. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Finding an analytical CRO that's truly invested in your success, not just processing samples, makes all the difference in CMC development. In this episode, host David Brühlmann talks with Daniel Galbraith, Chief Scientific Officer at Solvias, about the essential questions and mindset that lead to breakthrough CRO partnerships.With nearly three decades in analytical development, spanning monoclonal antibodies, biosimilars, and cell and gene therapies, Daniel reveals what separates CROs who become true partners from those who just run methods. His insights can save your program months of delays and costly missteps.Key Topics Discussed:Why cell and gene therapies face unique challenges compared to the progression seen with monoclonal antibodies (03:04)Daniel's career path: from entering biotech in 1996 to CSO at Solvias, and the rapid evolution of the industry (05:00)The analytical hurdles in characterizing cell-based products and how their inherent variability impacts development (09:46)Approaches to analytical method requirements for autologous cell therapies, and how data is gathered iteratively in these cases (13:02)The biggest obstacles to scaling up cell and gene therapies, and why innovative cell manipulation technologies are needed (16:06)Current trends in therapeutic modalities: why antibody-drug conjugates stand out, and whether mRNA therapies are losing momentum (18:37)Practical advice on choosing an analytical CRO as a strategic partner - what to look for, what questions to ask, and why enthusiasm and standardization matter (21:55)Wondering how to streamline your own analytical strategy, or navigate the parallel universe of cell and gene therapy development? Dig into this episode for Daniel's insider perspective. Then consider how the right analytical partnership could accelerate your path to clinic.Connect with Daniel Galbraith:LinkedIn: www.linkedin.com/in/daniel-galbraith-26a6138Solvias website: www.solvias.comEmail: daniel.galbraith@solvias.comNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callPreparing for your IND? Grab our Startup Founder CMC Dashboard in Notion to help you track tasks, timelines, and risks in one place at https://stan.store/SmartBiotech/p/discovertoind-cmc-dashboard-for-startup-founders

Hunter Grad, CEO and founder of Ameliogenix, joins the show to talk about developing mRNA immunotherapies for cardiovascular disease. George K and George A sit down with Hunter to discuss: How a procrastinated university project turned into a biotech startup tackling the leading cause of death worldwide The novel application of mRNA technology to permanently reduce cholesterol levels through targeting proteins within the body rather than viral diseases What it takes to bootstrap a biotech company in Ottawa, not Silicon Valley The brutal realities of fundraising in biotech versus software startups, and why pivoting isn't always an option when lives are on the line Clearing up the myths and misinformation around mRNA technology, from how it actually works to addressing fertility concerns The role of machine learning in accelerating biotech research and drug discovery, and why quality data matters more than flashy AI hypeHunter breaks down complex immunology concepts into digestible explanations while sharing the raw challenges of being a young founder in a traditionally academic-led industry. This episode explores innovation at the intersection of technology and medicine, the importance of rigorous science over buzzwords, and what it means to swing for the fences on a problem that affects 2 billion people worldwide.Mentioned:Using AI, MIT researchers identify a new class of antibiotic candidates

Aaron Siri was RFK's personal campaign lawyer and continues to fight for people who were injured by vaccines, mRNA, and government mandates. After filing FDA petitions for stronger Tylenol warning labels, he was the subject of a hit piece in the New York Times – one of our nation's highest honors. Georgia studio founder Ryan Millsap says Antifa-linked activists waged a four-year campaign of arson, vandalism, and harassment after his land swap deal near Atlanta's “Cop City.” Millsap, who built the famous Blackhall Studios, says Antifa's pressure derailed his projects and endangered his family. He now applauds President Trump's move to designate Antifa a domestic terror group, calling it long overdue. Aaron Siri is the Managing Partner of Siri & Glimstad LLP and has extensive experience in complex civil litigation matters and class actions. He handles civil rights, informed consent, and high-stakes disputes. He is the author of “Vaccines Amen: The Religion of Vaccines.” Learn more at https://sirillp.com and follow him at https://x.com/AaronSiriSG Ryan Millsap is the Chairman and CEO of Blackhall Studios, the Atlanta-based production facility behind films like “Venom,” “Jumanji,” and “Jungle Cruise.” In 2021, he sold the studio to Commonwealth Group, now Shadowbox Studios. An entrepreneur and investor, Millsap has revitalized communities through real estate and film. He is also the host of The Blackhall Podcast. Follow at https://x.com/RCMillsap 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠https://kalebnation.com⁠ • Susan Pinsky - ⁠https://x.com/firstladyoflove⁠ Content Producer & Booking • Emily Barsh - ⁠https://x.com/emilytvproducer⁠ Hosted By • Dr. Drew Pinsky - ⁠https://x.com/drdrew⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In his weekly clinical update, Dr. Griffin and Vincent Racaniello ponder the nomination of Casey Means for Surgeon General by President Trump, how mRNA vaccines may enhance effectiveness of check point inhibitor cancer therapies, if viral infection associates with cardiac disease, H5N1 isolation from backyard birds and turkey farms, and the effectiveness of the COVID-19, RSV and influenza vaccines before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, if revaccination with the mRNA RSV vaccine is effective, how effective today's COVID-19 vaccine is for protection against severe disease following infection with current viral variants, where to find PEMGARDA, how to access and pay for Paxlovid, can you be retreated with Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode The Challenge of Malignancies in HIV-1, Beyond Immune Activation and Back to Decreased Immune Surveillance (Journal of AIDS & Clinical Research) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (Nature) TWiV 1265: mRNA vaccines make cancer treatment great again (microbeTV: TWiV 1265) Viral Infections and Risk of Cardiovascular Disease (Journal of the American Heart Association) Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks (USDA: Animal and Plant Health Inspection Service) Three large turkey farms in Minnesota hit with H5N1 avian flu (CIDRAP) Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 (NEJM) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles vaccine recommendations from NYP (jpg) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: Cliff notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years (CID) Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England (LANCET: Infectious Diseases) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans (NEJM) Durability of 2024-2025 COVID-19 Vaccines Against JN.1 Subvariants (JAMA: Internal Medicine) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1266 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Freedom Angels founders Denise Aguilar and Tara Thorton describe how they (a former gang member and a former liberal) came together under the common mission to protect children in California against state leadership hell-bent on doing irreparable damage to them.  In this episode the Freedom Angels warn the rest of the nation about Governor Gavin Newsom who wants to be President more than anything on the planet and will stop at nothing in that pursuit. Newsom used isolation and fear tactics to force the mRNA vaccine on the public, created a sanctuary state to sterilize and mutilate children, strip parental rights, and put Californians in peril for his own political aspirations. Now, Newsom's massive gerrymandering scheme aims to steal 5 congressional seats in California with next week's special election. The Freedom Angels have a plan to fight back against California's disastrous leadership starting at the local level.

[00:07:39] – The Manchurian Candidate of Global ChaosKnight says Trump's tariffs are designed not to help U.S. workers but to destabilize global markets—“a Manchurian candidate for the globalists.” He contrasts Reagan's targeted trade policy with Trump's chaos-driven protectionism that punishes allies and wrecks economies. [00:16:01] – Corruption, Lawsuits & Impeachable CrimesKnight accuses Trump of weaponizing the Justice Department and tariffs for personal gain, coercing media companies like CBS. He argues these acts meet the constitutional standard for impeachment, proving Trump's authoritarian mindset and disregard for lawful restraint. [00:33:49] – The Soros Connection & Doublethink PoliticsKnight exposes Trump's Treasury Secretary Scott Besant's financial history with George Soros, mocking MAGA supporters for ignoring the hypocrisy. He says the movement's “doublethink”—defending globalist ties while claiming to fight them—reveals Trumpism as a psychological cult, not a populist movement. [01:10:22] – MRNA in the Food SupplyKnight details the USDA's approval of mRNA shots for livestock under Trump, calling it a “food contamination program.” He links the policy to Bill Gates–backed biotech efforts to genetically alter food and human biology through state-controlled agriculture. [01:33:42] – The ICE Weapons SurgeKnight reveals ICE's weapons budget has exploded 700% under Trump's second term, transforming the agency into a domestic army. He calls it the foundation of a “digital police state” merging border control with total surveillance infrastructure. [02:10:29] – Genocide in Nigeria: Equipping the PersecutedKnight interviews missionary filmmaker Jud Saul, who exposes mass Christian killings by Fulani militants. Saul blames Obama-era operatives for helping Muslim factions seize power and condemns U.S. silence as millions of Nigerian Christians are slaughtered or displaced. [02:17:00] – China's Exploitation of the Killing FieldsSaul reveals that Chinese mining companies are seizing land from murdered Christians with terrorist cooperation. Knight calls it “globalism's true face”—Beijing profiting from genocide while Western governments look away. [02:33:45] – Venezuela, Trump & the Next U.S. WarKnight closes with Trump's military escalation in Venezuela, calling his “war on drugs” a lie to seize oil fields. Comparing Trump to Duterte and Obama, he warns that MAGA's militarism will drag the U.S. into endless foreign wars and destroy what remains of constitutional liberty. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

This week on The Roseanne Barr Podcast, Roseanne Barr sits down with staunch constitutional lawyer and columnist Josh Hammer to untangle one of the messiest right-wing firesides: the leaked group chat from Charlie Kirk, the blogging blitz from Candace Owens, and what it means for freedom of speech, donor power, and the future of the conservative movement. From how Candace dropped screenshots of Kirk's private messages accusing donors of “bullying” him over Israel, to Hammer's push-back in public about what really happened behind the scenes, we cover it here.  The Right is imploding from within, and the least we can do is cover it with the kind of real talk and humor you expect from Roseanne.  JOSH HAMMER: https://x.com/josh_hammer https://a.co/d/hR8BPVC Sponsored By: The Wellness Company The only beef I trust — Wellness Farms by The Wellness Company. 100% grass-fed, no mRNA, no hormones, no vaccines! Order now at https://www.twc.health/RB and use code RB to save up to $90 and get free shipping on your Wellness Farms order. StopBox USA Get firearm security redesigned with StopBox USA — no batteries, no keys, just instant access when you need it. Save 15% with code ROSEANNE at https://www.stopboxusa.com/ROSEANNE #StopBoxPod” ------------------------------------------------ Follow Roseanne:     Website: https://www.roseannebarr.com Instagram: https://www.instagram.com/officialroseannebarr    Facebook: https://www.facebook.com/officialroseannebarr   Twitter: https://twitter.com/therealroseanne   YouTube: https://www.youtube.com/roseanneworld Rumble: https://rumble.com/user/roseannebarrpodcast Merch: https://www.roseannebarr.com/shop ------------------------------------------------ Co-host /Producer: Jake Pentland https://twitter.com/jakezuccproof https://www.instagram.com/jakepentlandzuccproof ------------------------------------------------ Music: "Synthetic World" by Swamp Dogg: https://youtu.be/2_uOB0455VI ------------------------------------------------